Skip to main content
. 2020 Jan 31;10:47. doi: 10.3389/fonc.2020.00047

Figure 2.

Figure 2

ZBTB7A suppresses OSCC oncogenicity. (A) Transient transfection of si-ZBTB7A decreases ZBTB7A protein expression (Lt), and increases cell migration as revealed by wound healing migration assays using OSCC cells (Middle and Rt). Wound closure is used to assess migration ability. (B,C) Western blot analysis. (B) This reveals the decrease in ZBTB7A expression present in the ZBTB7A knockdown (sh-ZBTB7A) cell subclones. (C) The findings also reveal expression of the fusion protein in the ZBTB7A-mGFP cell subclones. (D) Summary of cell cycle profiles of the ZBTB7A knockdown and exogenous expression SAS cell subclones. The cell cycle phases in the synchronized cell subclones after CDDP treatment for 24 h are shown. For details, please refer to Figure S4. (E–G) Oncogenicity. (E) Increases and decreases in oncogenicity can be seen with the ZBTB7A knockdown and exogenous expression SAS cell subclones, respectively. (F) Increased proliferation, migration, invasion and anchorage-independent colony formation occur with the ZBTB7A knockdown cell subclone of FaDu. (G) miR-372 associated changes in proliferation (Upper), migration (Lower Lt), and invasion (Lower Rt) of SAS cells are rescued by exogenous ZBTB7A expression. ns, not significant, *p < 0.05; **p < 0.01; ***p < 0.001.